Log in

NASDAQ:PETX - Aratana Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$4.92
0.00 (0.00 %)
(As of 07/18/2019)
Today's Range
$4.92
Now: $4.92
$4.92
50-Day Range
$4.92
MA: $4.92
$4.92
52-Week Range
$3.30
Now: $4.92
$7.16
VolumeN/A
Average Volume1.03 million shs
Market Capitalization$241.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.41 million
Book Value$2.07 per share

Profitability

Net Income$-14,720,000.00

Miscellaneous

Employees83
Market Cap$241.08 million
Next Earnings DateN/A
OptionableOptionable

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.


Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. View Aratana Therapeutics' Earnings History.

What price target have analysts set for PETX?

4 brokerages have issued 12-month price targets for Aratana Therapeutics' shares. Their forecasts range from $4.14 to $5.00. On average, they expect Aratana Therapeutics' stock price to reach $4.73 in the next twelve months. This suggests that the stock has a possible downside of 4.0%. View Analyst Price Targets for Aratana Therapeutics.

What is the consensus analysts' recommendation for Aratana Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.

Has Aratana Therapeutics been receiving favorable news coverage?

Headlines about PETX stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aratana Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Aratana Therapeutics.

Who are some of Aratana Therapeutics' key competitors?

What other stocks do shareholders of Aratana Therapeutics own?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
  • Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
  • Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
  • Mr. Brent A. Standridge, Consultant (Age 61)
  • Ms. Rachel Reiff, Head of Corp. Communications

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $4.92.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.

What is Aratana Therapeutics' official website?

The official website for Aratana Therapeutics is http://www.aratana.com/.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  396 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  669
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel